Sangamo Therapeutics (SGMO) Payables (2016 - 2025)
Historic Payables for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $15.6 million.
- Sangamo Therapeutics' Payables fell 2139.86% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.6 million, marking a year-over-year decrease of 2139.86%. This contributed to the annual value of $15.5 million for FY2024, which is 148.11% up from last year.
- Sangamo Therapeutics' Payables amounted to $15.6 million in Q3 2025, which was down 2139.86% from $10.7 million recorded in Q2 2025.
- Over the past 5 years, Sangamo Therapeutics' Payables peaked at $22.4 million during Q4 2022, and registered a low of $8.0 million during Q3 2021.
- For the 5-year period, Sangamo Therapeutics' Payables averaged around $14.8 million, with its median value being $15.5 million (2023).
- In the last 5 years, Sangamo Therapeutics' Payables tumbled by 5540.03% in 2021 and then skyrocketed by 12971.62% in 2022.
- Quarter analysis of 5 years shows Sangamo Therapeutics' Payables stood at $9.8 million in 2021, then surged by 129.72% to $22.4 million in 2022, then plummeted by 31.93% to $15.3 million in 2023, then rose by 1.48% to $15.5 million in 2024, then increased by 0.46% to $15.6 million in 2025.
- Its Payables was $15.6 million in Q3 2025, compared to $10.7 million in Q2 2025 and $18.2 million in Q1 2025.